Abstract
We have previously shown that ONO-2952, a novel 18-kDa translocator protein (TSPO) antagonist, inhibits stress-induced accumulation of neurosteroids and noradrenaline release in the rat brain and alleviates the subsequent symptomatic responses with a brain TSPO occupancy of 50% or more. In this study, we measured ONO-2952 brain TSPO occupancy in conscious rhesus monkeys using positron emission tomography (PET) with 11C-PBR28 as ligand for translational research to clinical application. PET scans were performed after single and repeated oral administration of ONO-2952 at several dose levels for each animal, with sequential arterial blood sampling. In vitro binding studies showed that ONO-2952 potently binds to brain TSPO in monkeys with an affinity equivalent to that in rats. ONO-2952, given orally before PET scans, dose dependently decreased 11CPBR28 uptake without marked brain region specificity. Results of the quantitative analysis using arterial input function revealed that TSPO occupancy after ONO-2952 single and repeated oral administration tended to increase in parallel with its plasma concentration, reaching the highest level of 100%. These findings indicate that ONO-2952 has sufficient brain distribution in primates and that ONO-2952 TSPO occupancy in humans can also be determined using PET.
Cite
CITATION STYLE
Mitsui, K., Morimoto, N., Niwa, T., Yamaura, Y., Ohba, H., Tsukada, H., & Katsumata, S. (2017). Quantification of ONO-2952 occupancy of 18-kDaTranslocator protein in conscious monkey brains using positron emission tomography. Journal of Pharmacology and Experimental Therapeutics, 360(3), 457–465. https://doi.org/10.1124/jpet.116.238568
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.